NeOnc Technologies Holdings, Inc.NTHI
Key ratios
FCF / Sales
-52921.5%TTM
2025
-50912.4%2024
-5078.2%2023
-2667.0%
ROA
-635.0%TTM
2025
-1166.5%2024
-190.7%2023
-507.6%
Revenue growth
100.0%TTM
2025
-51.8%2024
17.8%2023
252.3%
Recent news
NeOnc' Phase 2 Data Could Put Cancer on the Ropes
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
Track NTHI in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer